Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 6/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalazine SCHEMBL27936543 | 0.88 | GSK3B (0.39) | GSK3BSCN9ACDC7IKBKBCCNT1 | |
| SCHEMBL15820238 | 0.84 | KDM4C (0.38) | GSK3BKDM4BKDM5CKDM5BCYP4F2 | |
| SCHEMBL15819703 | 0.82 | GSK3B (0.32) | GSK3BF7 | |
| Phthalazinone SCHEMBL14249920 | 0.80 | ALDH1A1 (0.52) | GSK3BSCN9ACDC7IKBKBCCNT1 | |
| SCHEMBL31219530 | 0.78 | KMT2A (0.42) | KDM5CSMN1; SMN2 | |
| SCHEMBL1440454 | 0.78 | PTPN11 (0.38) | GSK3BJAK2CYP4F2CYP4A11TSHR | |
| SCHEMBL14250509 | 0.76 | ROCK2 (0.40) | GSK3BCDC7CDK2CYP4F2CYP4A11 | |
| SCHEMBL2295486 | 0.73 | MKNK1 (0.39) | GSK3BCDC7IKBKBCCNT1JAK2 | |
| SCHEMBL27938032 | 0.72 | — | — | |
| SCHEMBL20505744 | 0.71 | GSK3B (0.46) | GSK3BSCN9ACDC7ADORA3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062088-B2 | CDK-inhibiting pyrrolopyrimidine carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing the same as active ingredient for preventing or treating hepatocellular carcinoma | SNU R&DB FOUNDATION (KR) | 2015-06-23 | — | — | US | claimed |
| EP-4720066-A1 | PYRROLOPYRIMIDINE CARBOXAMIDES | Astrazeneca AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720066-A1 | PYRROLOPYRIMIDINE CARBOXAMIDES | Astrazeneca AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024252276-A1 | PYRROLOPYRIMIDINE CARBOXAMIDES | ASTRAZENECA AB (SE) | 2024-12-12 | — | — | WO | disclosed |
| US-20230398126-A1 | RIFT VALLEY FEVER SMALL MOLECULE TREATMENT | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2023-12-14 | — | — | US | disclosed |
| US-20200123499-A1 | METHOD FOR EFFICIENT GENERATION OF NEURONS FROM NON-NEURONAL CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2017096326-A1 | METHOD FOR EFFICIENT GENERATION OF NEURONS FROM NON-NEURONAL CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-08 | — | — | WO | disclosed |
| CN-103582644-B | Phthalazinone-Pyrrolopyrimidine Carboxamide Derivatives | 塔科达有限责任公司 | 2016-07-20 | — | — | CN | disclosed |
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20160108049-A1 | Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | disclosed |
| CN-101959890-B | Pyrrolopyrimidine carboxamides | NYCOMED GMBH | 2013-10-30 | — | — | CN | disclosed |
| CN-101959890-B | Pyrrolopyrimidine carboxamides | NYCOMED GMBH | 2013-10-30 | — | — | CN | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| EP-2470536-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023693-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-03-03 | — | — | WO | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| CN-101959890-A | Pyrrolopyrimidine carboxamides | NYCOMED GMBH | 2011-01-26 | — | — | CN | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398126-A1 | RIFT VALLEY FEVER SMALL MOLECULE TREATMENT | RIF1, XPOT, XPO5 | GSK3B 2760/4885SCN9A 1505/4885CDC7 2403/4885 |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | GSK3B 2798/4885SCN9A 893/4885CDC7 2705/4885 |
| US-20160108049-A1 | Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives | PDE4A, PDE4B, PDE5A | GSK3B 3805/4885SCN9A 837/4885CDC7 1535/4885 |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | GSK3B 2539/4885SCN9A 2014/4885CDC7 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.